Ten‐year immune persistence and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in females vaccinated at 15–55 years of age

• Published in: Cancer medicine (Malden, MA) Vol. 6; no. 11; pp. 2723 - 2731
• Main Authors: Schwarz, Tino F., Galaj, Andrzej, Spaczynski, Marek, Wysocki, Jacek, Kaufmann, Andreas M., Poncelet, Sylviane, Suryakiran, Pemmaraju V., Folschweiller, Nicolas, Thomas, Florence, Lin, Lan, Struyf, Frank
• Format: Journal Article
• Language: English
• Published: United States John Wiley and Sons Inc 01.11.2017
• Subjects: Adolescent; Adult; Antibodies, Viral - analysis; Antibodies, Viral - blood; AS04‐HPV‐16/18 vaccine; Bodily Secretions - immunology; Cancer Prevention; Cervix Uteri - immunology; Female; Follow-Up Studies; Human papillomavirus 16 - immunology; Human papillomavirus 18 - immunology; Humans; Middle Aged; older women; Original Research; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - adverse effects; Papillomavirus Vaccines - immunology; persistence; safety; Uterine Cervical Neoplasms - prevention & control; Vaccination - adverse effects; Vagina - immunology; Young Adult; AS04-HPV-16/18 vaccine; persistence; older women; safety

Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown. We investigated the 10‐year immune response and long‐term safety profile of the HPV‐16/18 AS04‐adjuvanted vaccine (AS04‐HP...